NEW YORK (GenomeWeb) – HER3 expression levels can distinguish colorectal cancer patients with wild-type RAS tumors who will respond to anti-EGFR therapy, according to a new study.

While RAS testing can identify colorectal cancer patients who won't respond to treatment with an anti-EGFR therapy like panitumumab, it doesn't necessarily identify patients who will benefit from such treatment.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.